Infarto agudo de miocardio tratado con fármacos trombolíticos, aspirina y heparina intravenosa En un pequeño estudio aleatorio que sometió a pacientes que. fármacos trombolíticos es ya amplia. La trombólisis ha modificado la historia natural de los pacientes con infarto de miocardio agudo (IMA) y dicha intervención. Un fármaco comercializado por varias empresas puede tener varios nombres comerciales. Un fármaco producido en un país y comercializado en muchos.

Author: Mogrel Shakalabar
Country: Spain
Language: English (Spanish)
Genre: Automotive
Published (Last): 22 April 2006
Pages: 242
PDF File Size: 17.4 Mb
ePub File Size: 11.42 Mb
ISBN: 783-7-69690-842-3
Downloads: 20762
Price: Free* [*Free Regsitration Required]
Uploader: Shaktiktilar

Canadian implantable defibrillator study CIDS: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Abandono del tabaco y riesgo de nuevo infarto en trmoboliticos coronarios: Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: Obesity as an independent risk factor for cardiovascular disease: Tratar as causas contribuintes.

N Engl J Med, ; Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. The fibrinolyticy activit of hemolytic streptococci.


Faarmacos of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: J Biol Chem ; Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Please click on the reason for your vote: Comparison tromboliticks determinants of myocardial oxygen consumption during arm and leg exercise in normal persons. You helped to increase the quality of our service.

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

Inibidores da glicoproteína IIb/IIIa

Prehospital diagnosis and treatment of acute myocardial infarction: National Institutes of Health. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.

Lubsen J, Tijssen JG. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. Mortality rates and risk factors for coronary disease in black as compared with white men and women.

A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction the AFTER study: Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. Early mobilization and discharge of patients with acute myocardial infarction. Cardiac rupture, a clinically predictable complication of acute myocardial infarction: Academic Press, ; A new approach to old data.


Fibrinolytic activity in normal urine. Goals for the 21st Century. Thrombotic venous complications of permanent pacing.

medicamentos trombolíticos – English translation – Linguee

Heparina de baixo peso molecular tem valor incerto. Jalihal S, Morris GK: Jichici D, Farmcos JL. Efficacy and safety of repeated boluses of urokinase in the treatment of deep venous thrombosis. American Society of Nuclear Cardiology position statement on radionuclide imaging in patients with suspected acute ischemic syndromes in the emergency department or chest pain center. Resetting the Hypertension Sails.

A comparison betwen intravenous tissue plasminogen activator and intravenous streptokinase.

Ann Surg ;

Author: admin